Notes

Benefits throughout robotic-assisted partial nephrectomy pertaining to imperative versus optional indications.
All participants with severe disease, 89.6% with mild to moderate infection, and 77.3% of asymptomatic participants had IgG antibodies to the RBD antigen. The threshold values for the nasopharyngeal viral RNA RT-PCR of a subset of asymptomatic and symptomatic seroconverters were comparable (P = 0.48) to those of nonseroconverters (P = 0.16) (N = 169). This is the first report of longitudinal humoral immune responses to SARS-CoV-2 over a period of 10 weeks in South Asia. The low seropositivity of asymptomatic participants and differences between assays highlight the importance of contextualizing the understanding of population serosurveys.In this issue of Cancer Research, Emami and colleagues leveraged genetic data from over 200,000 men of European descent to implicate rare alleles that are associated with prostate cancer. However, this study went beyond a simple description of statistical associations between genetic variants and cancer risk. Polygenic risk scores were applied to large cohorts from Kaiser Permanente and the UK Biobank, demonstrating the clinical utility of genetic predictors of disease risk. Furthermore, by placing their results in an evolutionary framework and integrating genetic information with functional data, the authors of this major study were able to bridge the gap between genome-wide association studies and the biological mechanisms underlying prostate cancer risk.See related article by Emami et al., 1695.Cranial radiation activates an upstream complement cascade component, C1q, leading to brain injury. Microglia-specific deletion of C1q prevents astrocyte and microglial activation, synaptic loss, neuroinflammation, and cognitive impairment. Therapeutically inhibiting complement activation may help mitigate radiation-induced cognitive decline.See related article by Markarian et al., p. 1732.Mdm2 and MdmX are two closely related proteins that have been well-characterized as negative regulators of the tumor suppressor p53. Their interplay and especially respective roles in ubiquitination and subsequent degradation of p53 have lacked clarity. Yang and colleagues now demonstrate an obligate role for MdmX in recruitment of the E2 ubiquitin ligase UbcH5c to the Mdm2-MdmX hetero-oligomer. The use of elegant genetically engineered mouse models ensures the biological relevance of their findings that have important implications for targeted therapies involving these key players in the p53 pathway.See related article by Yang et al., Cancer Res 2021;81898-909.Cardiomyopathy is a significant source of morbidity and early mortality among survivors of childhood cancer, and may disproportionately affect minorities. However, there have been few studies evaluating these outcomes among racially and ethnically diverse survivor populations. SCH900353 solubility dmso A study by Sapkota and colleagues systematically characterizes disparities in the incidence of treatment-associated cardiomyopathy on the basis of genetic ancestry and investigates genetic variants responsible for this inequality. The noteworthy findings include a disproportionate risk of cardiomyopathy among African-American childhood cancer survivors and the identification of inherited genetic variants, which may confer increased susceptibility to cardiomyopathy among these individuals. Although larger studies are needed to confirm these findings, incorporating this knowledge into clinical risk profiles may help focus attention on patient populations who are particularly vulnerable to adverse cardiovascular outcomes and most likely to benefit from preventive strategies.See related article by Sapkota et al., p. 2556.The DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a large protein kinase and a member of the PI3K-related family of protein kinases that also includes ATM and ATR. DNA-PKcs is a unique evolutionary endowment of higher eukaryotes, as it is absent in lower eukaryotes. It is central to the processing of DNA double-strand breaks by classical nonhomologous end-joining, where through interaction with the Ku70/Ku80 heterodimer it generates the DNA-PK holoenzyme. DNA-PK coordinates and regulates the joining of DNA ends through essential structural contributions and by direct phosphorylation of key repair factors, including itself. Recent structural studies advance our understanding of the functions of this giant enzyme and reveal functional complexity and sophistication compatible with a broad spectrum of activities. Along these lines, the observations reported in the article by Güllülü and colleagues in this issue of Cancer Research reveal intriguing new facets in the regulation of DNA-PKcs and open horizons for further exciting research. Güllülü and colleagues found that in addition to known modes of regulation, DNA-PKcs is also regulated by a direct interaction with survivin. The observations expand the functional and regulatory spectrum of this intriguing kinase and suggest contributions to DNA damage response that remain to be characterized. They formed the foundations for the development of drugs disrupting this interaction, thereby potentially sensitizing tumor cells to radiation.See related article by Güllülü et al., p. 2304.In this issue, Kamata-Sakurai and colleagues describe an agonist antibody to CD137 (4-1BB) that takes on an active conformation in environments with high ATP concentrations, characteristic of tumors. This represents a novel advancement in developing immunotherapies that can be administered systemically, but act locally to induce antitumor immune responses without the usual attendant toxicities.See related article by Kamata-Sakurai et al., p. 158.Guanine nucleotide exchange factors (GEF) control the rate-limiting step of physiologic RAS activation. In this issue of Cancer Discovery, Hofmann and colleagues describe the discovery of a selective inhibitor targeting the GEF, SOS1, along with its preclinical effects in suppressing KRAS-mutant tumor growth.See related article by Hofmann et al., p. 142.In this issue of Cancer Discovery, Yap and colleagues demonstrate in a phase I trial enrolling 22 patients diagnosed with advanced solid tumors that BAY 1895344, a new potent and specific ATR inhibitor, is safe and able to induce durable responses in ATM-deficient tumors. This compelling clinical activity paves the way for innovative combination regimens that rely on exploitation of DNA damage response defects in cancer.See related article by Yap et al., p. 80.
Here's my website: https://www.selleckchem.com/products/mk-8353-sch900353.html